Overview
PEPS ranks this pair inside the Top 300 market-cap universe. That means USTB and Injective are liquid enough for an indexable comparison, with metrics refreshed on the hourly coin pipeline.
Quick winners
Full comparison
| Metric | USTB | INJ |
|---|---|---|
| Price | $1,847.95 | $4.97 |
| Market Cap | $893.12M | $490.41M |
| FDV | — | — |
| Volume 24h | $0.000000 | $3.42M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 71.00 | 100.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +3.50% | +5.78% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | USTB | INJ |
|---|---|---|
| 1H | — | — |
| 24H | +0.00% | +0.95% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | USTB | INJ |
|---|---|---|
| RSI | 54.31 | 53.92 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 66.45 | 0.29 |
| ADX | 20.44 | 12.69 |
| Support | 1,827.82 | 4.91 |
| Resistance | 1,960.30 | 5.03 |
| Trend | bearish | neutral |
| Momentum | 63.00 | — |
| Signal | neutral | neutral |
Automatic technical analysis
Indicator stacks for USTB/INJ currently lean on separate regimes: bearish versus neutral. Treat MACD and RSI as context, not as standalone entry triggers.
Fundamentals
| Metric | USTB | INJ |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | — | 0.00 |
| Github activity | — | 118.00 |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
USTB
Injective
Pros and cons
Pros of USTB
- USTB often anchors narratives that attract sustained media and analyst coverage.
- Market-cap scale on USTB may dampen some idiosyncratic shocks versus smaller peers.
- Higher ranking for USTB can translate into tighter spreads on major venues.
- USTB typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
Cons of USTB
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
- Indicator stacks on USTB may stay stretched longer than expected in strong trends.
- Regulatory or macro headlines can hit USTB harder simply because it is more visible.
- Crowded positioning around USTB sometimes amplifies squeeze or flush risk.
Pros of Injective
- Injective can offer higher relative beta when market attention rotates toward its niche.
- Diversifying versus USTB with Injective can change portfolio factor exposure.
Cons of Injective
- Relative underperformance versus USTB can persist through entire market regimes.
- Incomplete fundamental coverage can hide operational or tokenomic risks.
- Smaller book depth versus large caps can increase slippage for Injective.
Which looks stronger right now?
Data currently points to a probabilistic edge for USTB on size and Injective on activity. Neither reading guarantees future returns.
AI summary
In about three hundred words of context: USTB (USTB) trades near $1,847.95 with a +0.00% day move, while Injective (INJ) is around $4.97 (+0.95%). Volume leadership currently sits with Injective, and market-cap leadership with USTB. Technical trend labels read bearish vs neutral, with RSI near 54.31/53.92. Bottom line: use this page as a structured checklist, then open each coin page and related PEPS tools before acting. Nothing here is financial advice.
FAQ
Which is better, USTB or Injective?
“Better” depends on horizon and risk. USTB leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, USTB or INJ?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both USTB and Injective.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.